Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
$40,175 per ton !
That’s $17,175 above the Shard forecast, and tungsten is also above their forecast ;-)
Come on WRES get the production figures up to nameplate levels.
Good luck Adrian have a great Christmas mate.
OMR
Falsies don’t count when your grinding mate ;-)
Topb
The SP has without doubt gotten worse !
The question is will it get better again ?
In my view it will, but, not until the company has proven that it can produce at or at least close to template production at La Parilla.
Additionally, for it to improve sufficiently for me to be back in profit, they will need to be producing from Regua as well.
If Q4 is very good, then you may see an SP above your 12p average, I however need a much higher SP before I will be back in profit-:( but, nil desperandum, it ain’t over until it’s over ;-)
Mullins
Yes indeed, let’s hope that Q4 is better than Q3 which we already know, was better than Q2, which we already know, was better than Q1 : and, that they are able to tell us that we are well on our way to reaching nameplate production.
Mullins
Just as I thought then, quarterly figures from now on exactly as most if not all miners do.
They’ve converted the CFDs and also purchased a further 0.23% as their percentage has increased from 15.341% to 15.571%
I’m pretty sure that we are going to get them quarterly from now onwards, which I’m not bothered about.
I wish all genuine WRES investors a great weekend ;-)
Mullins
The tin prices have fluctuated between a low of $37,625 and a high of $39,627 over the last month.
If we look at the last 6 months the low is $27,300.
If we look at the last year the low is $17,600, and that was when the world was in a far worse place with covid than today and many major economies were in lockdown.
Everything is set for tin to stay at a much higher level than expected by Shard;-)
Troajan
It is about sentiment mate, WRES needs to prove that production can increase significantly and get to nameplate level at la parilla, if that happens and I believe it will, then the SP will recover substantially, and if subsequently in H2 2022, we do get Regua up and running I might even finally get to see a profit on my investment ;-)
Safety
I have no doubt that the comments in the, so far today, 13 green boxes ! Are far from altruistic, and what’s more I have no doubt that they all contain comments that either denigrate the company, the CEO, and or genuine investors - that’s why I have them filtered mate ;-)
Despite green boxes outnumbering proper posts, it would seem that more people believe that WRES will succeed than think it won’t.
Good luck to all genuine WRES investors ;-)
There was no promise of ongoing monthly production reports.
We may get them but my guess is that we won’t.
I don’t think we will get monthly production figures but time will tell.
Mac
RM decided to go ahead with our own trials, the UK still deemed our trial to be and urgent public health study, obviously it would be great if the UK government placed a massive order for SNG001, and they may well do so, but not until we have the phase 3 results mate, the same as the FDA in America, they want substantial proof, but, when we have that proof I have no doubt that both governments, and others as well, will be all over SNG.
This is directly from an RNS in January this year :-
The FDA are all over the sprinter phase 3 trial, this is an excerpt from the RNS in January:-
“As previously announced, Synairgen has appointed Parexel Biotech, a division of the leading global clinical research organisation, Parexel, to help conduct the Phase III trial and several UK sites have now been initiated, with further sites in the US and the EU expected to follow. The trial is deemed an Urgent Public Health study by the UK's National Institute for Health Research (NIHR). In the US, SNG001 has been granted Fast Track status from the US Food and Drug Administration (FDA). The Company is seeking further equivalent prioritisations and support from governments in participating countries.“
Fizzy
No relationship currently exists between AZ and SNG
Dan
I think EUA approval is nailed on if the Sprinter trial is, as expected, successful, and that the FDA will subsequently go for full approval, I don’t think anyone knows if they will want to await the Active111 results before full approval is granted, time will tell.
Dan
The FDA are all over the sprinter phase 3 trial, this is an excerpt from the RNS in January:-
“As previously announced, Synairgen has appointed Parexel Biotech, a division of the leading global clinical research organisation, Parexel, to help conduct the Phase III trial and several UK sites have now been initiated, with further sites in the US and the EU expected to follow. The trial is deemed an Urgent Public Health study by the UK's National Institute for Health Research (NIHR). In the US, SNG001 has been granted Fast Track status from the US Food and Drug Administration (FDA). The Company is seeking further equivalent prioritisations and support from governments in participating countries.“
So, there is every likelihood that good results from sprinter will lead to FDA approval, indeed RM has stated that we are gearing up to apply for an EUA if the sprinter trial results prove effectiveness.
Pattagucci
If there are no deaths (from covid) amongst those given SNG in the phase 3 sprinter trial, and of course if the efficacy is anywhere near as high as phase 2, it will be a brilliant result, a game changer, and the SP will without doubt rocket.